Join to View Full Profile
300 W 10th AveColumbus, OH 43210
Phone+1 614-293-5066
Fax+1 614-293-9449
Dr. Burns is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Timothy Burns is an oncology specialist based in Columbus, OH, with a subspecialty in thoracic cancer. He completed his fellowship in Hematology and Medical Oncology and his residency in Internal Medicine at Johns Hopkins University, and he is an alumnus of the Perelman School of Medicine at the University of Pennsylvania. He is currently a Professor of Medicine at The Ohio State University Comprehensive Cancer Center. Previously, he served as an Associate Professor of Medicine at UPMC Magee-Womens Hospital and UPMC Presbyterian Shadyside until 2024. Dr. Burns has experience in lung cancer and targeted therapy and has contributed to several publications on related topics. He has led clinical trials, including research on genetic markers of lung cancer and advanced solid tumors. He has also received CMS Meaningful Use Stage 1 certification for Medical Oncology from Varian Medical Systems.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011- Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
Perelman School of Medicine at the University of PennsylvaniaClass of 2005
Certifications & Licensure
OH State Medical License 2024 - 2026
PA State Medical License 2012 - 2024
MD State Medical License 2008 - 2012
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2015-2016
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2015-2016
Clinical Trials
- Detection of Genetic Markers of Lung Cancer
- Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
- A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours Start of enrollment: 2024 Jul 31
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype.Timothy F Burns, Sanja Dacic, Anish Chakka, Ethan Miller, Maria A Velez
The Journal of Clinical Investigation. 2025-12-18 - Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.Timothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Dae Ho Lee, Takafumi Koyama
Journal of Thoracic Oncology. 2025-11-29 - Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).Liza C Villaruz, Jingxiao Jin, Hong Wang, James J Lee, Jason J Luke
Cancer. 2025-11-01
Press Mentions
Taking on Acquired Resistance in EGFR-Mutant NSCLCNovember 1st, 2024- FDA Approves Amgen Drug for Permanently Fatal Form of Lung CancerMay 16th, 2024
- Lung Cancer Survival Rate in Pennsylvania Improves, Report ShowsNovember 15th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
